My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 1285

    1.

    Control of postprandial plasma glucose by an oral insulin product (HIM2) in patients with type 2 diabetes.

    Kipnes M, Dandona P, Tripathy D, Still JG, Kosutic G.

    Diabetes Care. 2003 Feb;26(2):421-6.PMID: 12547873 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Oral insulin product hexyl-insulin monoconjugate 2 (HIM2) in type 1 diabetes mellitus: the glucose stabilization effects of HIM2.

    Clement S, Still JG, Kosutic G, McAllister RG.

    Diabetes Technol Ther. 2002;4(4):459-66.PMID: 12396740 [PubMed - indexed for MEDLINE]Related articles

    3.

    Pharmacology and tolerability of a single dose of exenatide in adolescent patients with type 2 diabetes mellitus being treated with metformin: a randomized, placebo-controlled, single-blind, dose-escalation, crossover study.

    Malloy J, Capparelli E, Gottschalk M, Guan X, Kothare P, Fineman M.

    Clin Ther. 2009 Apr;31(4):806-15.PMID: 19446153 [PubMed - indexed for MEDLINE]Related articles

    4.

    Dose-response effect of a single administration of oral hexyl-insulin monoconjugate 2 in healthy nondiabetic subjects.

    Wajcberg E, Miyazaki Y, Triplitt C, Cersosimo E, DeFronzo RA.

    Diabetes Care. 2004 Dec;27(12):2868-73.PMID: 15562199 [PubMed - indexed for MEDLINE]Related articlesFree article

    5.

    Oral modified insulin (HIM2) in patients with type 1 diabetes mellitus: results from a phase I/II clinical trial.

    Clement S, Dandona P, Still JG, Kosutic G.

    Metabolism. 2004 Jan;53(1):54-8.PMID: 14681842 [PubMed - indexed for MEDLINE]Related articles

    6.

    Pramlintide reduces postprandial glucose excursions when added to regular insulin or insulin lispro in subjects with type 1 diabetes: a dose-timing study.

    Weyer C, Gottlieb A, Kim DD, Lutz K, Schwartz S, Gutierrez M, Wang Y, Ruggles JA, Kolterman OG, Maggs DG.

    Diabetes Care. 2003 Nov;26(11):3074-9.PMID: 14578242 [PubMed - indexed for MEDLINE]Related articlesFree article

    7.

    Exenatide: effect of injection time on postprandial glucose in patients with Type 2 diabetes.

    Linnebjerg H, Kothare PA, Skrivanek Z, de la Peña A, Atkins M, Ernest CS, Trautmann ME.

    Diabet Med. 2006 Mar;23(3):240-5.PMID: 16492205 [PubMed - indexed for MEDLINE]Related articles

    8.

    Improved postprandial glycemic control with Humalog Mix75/25 after a standard test meal in patients with type 2 diabetes mellitus.

    Malone JK, Woodworth JR, Arora V, Yang H, Campaigne BN, Hallé JP, Yale JF, Grossman LD.

    Clin Ther. 2000 Feb;22(2):222-30.PMID: 10743981 [PubMed - indexed for MEDLINE]Related articles

    9.

    Pramlintide reduces postprandial glucose excursions when added to insulin lispro in subjects with type 2 diabetes: a dose-timing study.

    Maggs DG, Fineman M, Kornstein J, Burrell T, Schwartz S, Wang Y, Ruggles JA, Kolterman OG, Weyer C.

    Diabetes Metab Res Rev. 2004 Jan-Feb;20(1):55-60.PMID: 14737746 [PubMed - indexed for MEDLINE]Related articles

    10.

    Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes.

    Juhl CB, Hollingdal M, Sturis J, Jakobsen G, Agersø H, Veldhuis J, Pørksen N, Schmitz O.

    Diabetes. 2002 Feb;51(2):424-9.PMID: 11812750 [PubMed - indexed for MEDLINE]Related articlesFree article

    11.

    Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison.

    Robbins DC, Beisswenger PJ, Ceriello A, Goldberg RB, Moses RG, Pagkalos EM, Milicevic Z, Jones CA, Sarwat S, Tan MH.

    Clin Ther. 2007 Nov;29(11):2349-64.PMID: 18158076 [PubMed - indexed for MEDLINE]Related articles

    12.

    Dose-response relationship of an oral insulin spray in six patients with type 1 diabetes: a single-center, randomized, single-blind, 5-way crossover study.

    Cernea S, Kidron M, Wohlgelernter J, Raz I.

    Clin Ther. 2005 Oct;27(10):1562-70.PMID: 16330292 [PubMed - indexed for MEDLINE]Related articles

    13.

    Efficacy comparison between preprandial and postprandial insulin aspart administration with dose adjustment for unpredictable meal size.

    Jovanovic L, Giammattei J, Acquistapace M, Bornstein K, Sommermann E, Pettitt DJ.

    Clin Ther. 2004 Sep;26(9):1492-7.PMID: 15531011 [PubMed - indexed for MEDLINE]Related articles

    14.

    Comparison of the pharmacokinetic and pharmacodynamic profiles of biphasic insulin aspart 50 and 30 in patients with type 2 diabetes mellitus: a single-center, randomized, double-blind, two-period, crossover trial in Japan.

    Hirao K, Maeda H, Urata S, Takisawa Y, Hirao S, Sasako T, Sasaki T.

    Clin Ther. 2007 May;29(5):927-34.PMID: 17697911 [PubMed - indexed for MEDLINE]Related articles

    15.

    A single-center, randomized, double-blind, three-way crossover study examining postchallenge glucose responses to human insulin 70/30 and insulin lispro fixed mixtures 75/25 and 50/50 in patients with type 2 diabetes mellitus.

    Schwartz S, Zagar AJ, Althouse SK, Pinaire JA, Holcombe JH.

    Clin Ther. 2006 Oct;28(10):1649-57.PMID: 17157120 [PubMed - indexed for MEDLINE]Related articles

    16.

    Randomized dose ranging study of the reduction of fasting and postprandial glucose in type 2 diabetes by nateglinide (A-4166).

    Gribble FM, Manley SE, Levy JC.

    Diabetes Care. 2001 Jul;24(7):1221-5.PMID: 11423506 [PubMed - indexed for MEDLINE]Related articlesFree article

    17.

    Humalog Mix25 offers better mealtime glycemic control in patients with type 1 or type 2 diabetes.

    Malone JK, Yang H, Woodworth JR, Huang J, Campaigne BN, Halle JP, Yale JF, Grossman LD.

    Diabetes Metab. 2000 Dec;26(6):481-7.PMID: 11173719 [PubMed - indexed for MEDLINE]Related articlesFree article

    18.

    Increased prandial insulin secretion after administration of a single preprandial oral dose of repaglinide in patients with type 2 diabetes.

    Owens DR, Luzio SD, Ismail I, Bayer T.

    Diabetes Care. 2000 Apr;23(4):518-23.PMID: 10857945 [PubMed - indexed for MEDLINE]Related articlesFree article

    19.

    Effect of a local heating device on insulin and glucose pharmacokinetic profiles in an open-label, randomized, two-period, one-way crossover study in patients with type 1 diabetes using continuous subcutaneous insulin infusion.

    Raz I, Weiss R, Yegorchikov Y, Bitton G, Nagar R, Pesach B.

    Clin Ther. 2009 May;31(5):980-7.PMID: 19539098 [PubMed - indexed for MEDLINE]Related articles

    20.

    The effect of combination treatment with acarbose and glibenclamide on postprandial glucose and insulin profiles: additive blood glucose lowering effect and decreased hypoglycaemia.

    Rosak C, Haupt E, Walter T, Werner J.

    Diabetes Nutr Metab. 2002 Jun;15(3):143-51.PMID: 12173728 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity